Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

NCT00969293 is registered in ClinicalTrials.gov with Fovea Pharmaceuticals SA as lead sponsor.

NCT NCT00969293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00969293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
Lead sponsor
Fovea Pharmaceuticals SA
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2009
Completion date
March 31, 2012
Enrollment
11 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

central retinal vein occlusion, macular edema